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ABSTRACT 
 
Cancerous diseases present a formidable health problem worldwide. While the 
chemotherapy of cancer, in conjunction with other treatment modalities, has reached a 
significant level of maturity, efficacious use of such agents is still restricted by numerous 
pharmacological deficiencies, such as poor solubility, short serum circulation lifetimes, 
and low bioavailability resulting from lack of affinity to cancer tissue and inadequate 
mechanisms of cell entry. More critically still, most drugs suffer from toxic side effects 
and a risk of drug resistance. In an attempt to enhance the therapeutic effectiveness of 
carcinostatic drugs, the concept of anchoring bioactive agents to polymeric carriers has 
proved to be a promising approach to overcome these deficiencies and was the main aim 
of this project. 
 
Water-soluble, biodegradable macromolecular carriers used were polyaspartam ides, 
prepared by an aminolytic ring-opening process of polysuccinimide; polyam ides obtained 
by ester-amine base-catalyzed polyaddition; and polyam idoam ines prepared by Michael-
type addition polymerization. The drug-anchoring potential of carrier polymers was 
demonstrated by the coupling of methotrexate (MTX), ferrocene and platinum drug 
models. 
 
MTX was linked to carrier via polymer attached amine by N-acylation of linear amine-
functionalized polyaspartamide carriers with the acid group from methotrexate. Acylation 
was brought about by mediation of HBTU coupling agent. The resulting MTX content of 
the conjugates was in the range of 10-19% by mass. 
 
In the present dissertation, series of water-soluble ferrocene conjugates were synthesized 
as for MTX by N-acylation of linear amine-functionalized polyaspartamide carriers with 
4-ferrocenylbutanoic acid. Acylation was brought about again by mediation of HBTU 
coupling agent. The resulting iron content of the conjugates was in the range of 6-13% by 
mass. 
 
 iv 
Polymer-attached dihydroxylato-type ligands were used to anchor the platinum drug to 
the polymeric carriers. The platinum content of the conjugates was in the range of 6-8% 
by mass. 
 
A member of selected conjugates was submitted to the Department of Immunology, 
University of Pretoria, and to the School of Pharmacy, University of California, Los 
Angeles, CA, for biomedical activity assessment. 
 
In order to demonstrate the multidrug-binding capacity of the polyaspartamide-type 
carriers, ferrocene was co-conjugated to selected polymeric conjugates containing MTX 
or folic acid. The latter was used to ensure target-specific drug delivery. 
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